ADVENTRX Pharmaceuticals Inc - Corporate and Strategic Assessment Report – Company Strategy, Financial and Operations Review
ADVENTRX Pharmaceuticals Inc - Corporate and Strategic Assessment Report – Company Strategy, Financial and Operations Review - companiesandmarkets.com adds new report
© companiesandmarkets.com
19.11.2008 23:51:02 ADVENTRX Pharmaceuticals Inc - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis - a new market research report on www.companiesandmarkets.com
(live-PR.com) - www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on anticancer and antiviral treatments that improve the performance and safety of existing drugs by addressing significant problems such as drug metabolism, toxicity, bioavailability or resistance. It has developed a strong proprietary pipeline as a result of its acquisition of SD Pharmaceuticals in April 2006
Scope
Contains corporate
strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
In November 2007, ADVENTRX decided to discontinue its Phase III clinical trial of CoFactor, its lead candidate, for the first-line treatment of metastatic colorectal cancer following advice received from the Data Safety Monitoring Board (DSMB).
Being a development stage company, ADVENTRX did not record any revenues over 2002-2006.
The company´s key objective is to advance clinical development of its lead candidate, CoFactor (ANX-510). To achieve this, Dendreon plans to enter into collaborations related to CoFactor.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on anticancer and antiviral treatments that improve the performance and safety of existing drugs by addressing significant problems such as drug metabolism, toxicity, bioavailability or resistance. It has developed a strong proprietary pipeline as a result of its acquisition of SD Pharmaceuticals in April 2006
Scope
Contains corporate
|
|
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
In November 2007, ADVENTRX decided to discontinue its Phase III clinical trial of CoFactor, its lead candidate, for the first-line treatment of metastatic colorectal cancer following advice received from the Data Safety Monitoring Board (DSMB).
Being a development stage company, ADVENTRX did not record any revenues over 2002-2006.
The company´s key objective is to advance clinical development of its lead candidate, CoFactor (ANX-510). To achieve this, Dendreon plans to enter into collaborations related to CoFactor.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
www.companiesandmarkets.com/Summary-Company-Prof ..
| Author: |
